Developer docs
API playgroundTry for free, no card

Search company profiles

Sentinel Diagnostics

Full company profile

uuid000am9m

Namestring
Sentinel Diagnostics
Legal namestring
SENTINEL CH. SpA
Company typeenum
Private
Founded yearint
2009
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMilano, Italy
HQ citystring
Milano
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, molecular diagnostics kits, clinical chemistry reagents, PCR assay development, diagnostic medical devices
Industry2 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1IVD Products Manufacturing and Sales
TypeOne Time License
Description

Sentinel Diagnostics generates revenue through the research, development, and manufacturing of In Vitro Diagnostic products. Product lines include molecular diagnostics (STAT-NAT kits for COVID-19, virology, VRE, parasitology), clinical chemistry, FIT (Fecal Immunochemical Test) line, and laboratory reagents. Products are sold directly to clinical laboratories and healthcare facilities.

sentineldiagnostics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Quote-based pricing for clinical laboratories
ModelOtherBilling cadenceMulti-year contract
Notes

Products are available for sale in EU and other selected countries. Not for sale in USA and Canada. Pricing is determined through direct contact with the company via export@sentinel.it.

sentineldiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1STAT-NAT®
Description

Stabilized Amplification Technology - proprietary technology that stabilizes enzyme activity for long-term storage without temperature-controlled requirements

sentineldiagnostics.com
+6 more records
Core offering1 text field

Sentinel Diagnostics researches, develops, and manufactures In Vitro Diagnostic (IVD) medical devices for clinical laboratories. Its portfolio includes proprietary lyophilized real-time PCR kits (STAT-NAT®) for molecular diagnostics, fecal immunochemical tests (FIT line) for colorectal cancer screening, clinical chemistry reagents, and automated instruments (SENTiNAT®, SENTiFIT®). Products are sold directly to clinical laboratories and healthcare facilities, primarily in the EU and selected international markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sentinel Diagnostics is a leader in Research and Development and Manufacturing of IVD (In Vitro Diagnostic) products based in Milan, Italy. The company operates three main product lines: (1) STAT-NAT® line featuring proprietary lyophilized real-time PCR technology for molecular diagnostics with room-temperature stable reagents, including COVID-19 molecular and serological assays, virology panels, healthcare-associated infection tests (VRE), and parasitology kits, supported by the SENTiNAT® instrument family (200, MICRO, X48); (2) FIT line providing Fecal Immunochemical Tests (FOB Gold®, CALiaGold®, PYLiaGold) for colorectal cancer screening, run on SENTiFIT® 270 automated analyzers; and (3) Laboratory line encompassing molecular biology reagents, clinical chemistry, dedicated reagents, and chromatography products acquired through Eureka S.r.l. The company also offers lyophilization services. Sentinel Diagnostics acquired Eureka S.r.l. in February 2023 to expand its diagnostic portfolio and assay offerings for clinical laboratories.

Product and service20 records
1STAT-NAT® molecular diagnostics line
CategoryMolecular Diagnostics
Description

Proprietary lyophilized real-time PCR technology platform with room-temperature stable reagents for molecular diagnostics. Includes kits for COVID-19, virology, healthcare-associated infections, and parasitology applications, sold to clinical laboratories.

2FIT line (Fecal Immunochemical Test)
CategoryClinical Chemistry / Immunoassay
Description

Fecal Immunochemical Test (FIT) product line for colorectal cancer screening, including FOB Gold®, CALiaGold®, and PYLiaGold assays paired with SENTiFIT® instruments, sold to clinical laboratories and screening programs.

3STAT-NAT® COVID-19 MULTI
CategoryMolecular Diagnostics - Respiratory
Description

Lyophilized one-step multiplex Real-Time RT-PCR mix for qualitative detection of SARS-CoV-2 RNA in human respiratory tract specimens, available in all-in-one tube and high-throughput formats for clinical laboratories.

4STAT-NAT® Pluri CoV-2-FLU-RSV
CategoryMolecular Diagnostics - Respiratory
Description

Multiplex Real-Time RT-PCR for simultaneous qualitative detection of SARS-CoV-2, Influenza A&B, and RSV in human respiratory specimens in a single reaction, used by clinical laboratories for respiratory pathogen differentiation.

5STAT-NAT® SARS-CoV-2 (3-gene)
CategoryMolecular Diagnostics - Respiratory
Description

3-gene based Real-Time RT-PCR kit for qualitative detection of SARS-CoV-2 targeting RdRp, N, and E genes, designed to be unaffected by virus mutations, for use in clinical laboratories.

6COVID-19 Anti-S1 Total Ab
CategorySerological Diagnostics
Description

Immunoturbidimetric test for quantitative and qualitative detection of total antibodies against the Spike RBD S1 protein of SARS-CoV-2 in human serum, run on SENTiFIT® analyzers in clinical laboratories.

7COVID-19 Anti-NC Total Ab
CategorySerological Diagnostics
Description

Immunoturbidimetric test for quantitative and qualitative detection of total antibodies against the Nucleocapsid protein of SARS-CoV-2 in human serum, run on SENTiFIT® analyzers.

8STAT-NAT® VRE
CategoryMolecular Diagnostics - Healthcare-Associated Infections
Description

Lyophilized Real-Time PCR mix for rapid detection of Vancomycin-Resistant Enterococcus (VRE), identifying and differentiating vanA and vanB genes in a single tube, for use in clinical and hospital laboratories.

9STAT-NAT® virology kits
CategoryMolecular Diagnostics - Virology
Description

Portfolio of lyophilized Real-Time PCR kits for virology applications including detection of HAdV, CMV, BKV, VZV, Parvo B19, HSV 1&2, HHV-6, HHV-7, HHV-8, EBV, and JCV, used by clinical laboratories.

10STAT-NAT® Leishmania spp.
CategoryMolecular Diagnostics - Parasitology
Description

STAT-NAT® kit for molecular detection of Leishmania spp. parasites, used in clinical and parasitology laboratories.

11STAT-NAT® Pathomag extraction kit
CategoryMolecular Diagnostics - Sample Preparation
Description

Magnetic beads-based nucleic acid extraction kit optimized for respiratory samples, enabling rapid purification of viral RNA/DNA and bacterial DNA, with 120 extractions per kit and room temperature storage.

12STAT-NAT® Total DNA/RNA extraction kit
CategoryMolecular Diagnostics - Sample Preparation
Description

Extraction kit for isolating pathogen RNA and DNA, compatible with multiple clinical sample types and designed for high extraction efficiency at low viral titers, used by clinical laboratories.

13SENTiNAT® 200
CategoryDiagnostic Instrument
Description

Sample-to-result PCR platform and walk-away system with automatic result interpretation, designed for medium to high-throughput automated molecular diagnostics workflows in clinical laboratories.

14SENTiNAT® MICRO
CategoryDiagnostic Instrument
Description

Compact PCR amplification instrument designed for manual molecular diagnostics workflows in clinical laboratory settings.

15SENTiNAT® X48
CategoryDiagnostic Instrument
Description

Automatic nucleic acid extraction and PCR set-up instrument used by clinical laboratories to prepare molecular diagnostics assays.

16SENTiFIT® 270
CategoryDiagnostic Instrument
Description

High-speed, fully automated quantitative analyzer for clinical chemistry and immunoturbidimetric assays, including FIT and serological tests, used in clinical laboratories.

17FOB Gold®
CategoryClinical Chemistry - FIT
Description

Fecal Immunochemical Test (FIT) assay for colorectal cancer screening, run on SENTiFIT® automated analyzers in clinical laboratories.

18CALiaGold®
CategoryClinical Chemistry - FIT
Description

Fecal Immunochemical Test (FIT) assay within the FIT product line, used for fecal immunochemical testing in clinical laboratories.

19PYLiaGold
CategoryClinical Chemistry - FIT
Description

Fecal Immunochemical Test assay variant within the FIT product line, used for pepsinogen testing in clinical laboratories.

20Chromatography products (Eureka)
CategoryChromatography Diagnostics
Description

Chromatography diagnostic kits acquired through the February 2023 acquisition of Eureka S.r.l., expanding Sentinel's diagnostic portfolio for clinical laboratories.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

In February 2023, Sentinel Diagnostics acquired Eureka S.r.l. to expand its diagnostic portfolio and assay offerings for clinical laboratories. This acquisition expanded Sentinel's product offerings in the chromatography space (referenced as www.eurekakit.com on their website).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-sized European IVD manufacturer offering molecular diagnostics (PCR) and clinical chemistry reagents to clinical laboratories — closely comparable scale and product structure to Sentinel.

TypeBroad incumbent
Description

Diversified diagnostics player with Panther molecular diagnostic systems and assays targeting women's health, infectious disease, and HAIs — competes with Sentinel for clinical-lab molecular placements.

TypeBroad incumbent
Description

World's largest IVD manufacturer covering molecular diagnostics, clinical chemistry, immunoassays, and laboratory automation — broadest incumbent reference benchmark for Sentinel's full portfolio.

TypeBroad incumbent
Description

Major provider of molecular diagnostics reagents, extraction kits, and PCR assays to clinical laboratories — directly competes in extraction and PCR reagent categories sold by Sentinel.

TypeEmerging player
Description

Molecular diagnostics company specializing in multiplex syndromic PCR assays (respiratory, gastrointestinal) — comparable technology overlap with Sentinel's STAT-NAT multiplex panels.

TypeBroad incumbent
Description

Global IVD leader with strong molecular diagnostics and clinical microbiology portfolios serving clinical laboratories — broad incumbent competing on respiratory panels, HAIs, and reagents.

TypeBroad incumbent
Description

Global leader in sample-to-result molecular diagnostics (GeneXpert) for infectious disease and healthcare-associated infections — competes head-to-head with SENTiNAT and STAT-NAT in clinical-lab molecular IVD.

TypeDirect peer
Description

Italian-headquartered IVD company with overlapping molecular diagnostics, clinical chemistry, and immunoassay product lines sold through clinical laboratories — direct European peer with similar customer base and product mix.

TypeRegional player
Description

Italian diagnostics manufacturer producing IVD reagents and clinical chemistry products for Italian and European clinical laboratories — comparable regional scale and end-market focus.

10Abbott Diagnostics
TypeBroad incumbent
Description

Global IVD leader with molecular (m2000, Alinity m), immunoassay, and clinical chemistry systems — competes across Sentinel's menu with clinical-laboratory customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sentinel Diagnostics

In Vitro Diagnosticssentineldiagnostics.com

Sentinel Diagnostics firmographics

Firmographics
Name
Sentinel Diagnostics
Legal name
SENTINEL CH. SpA
Website
https://sentineldiagnostics.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Sentinel Diagnostics industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • In vitro diagnostics
  • Molecular diagnostics kits
  • Clinical chemistry reagents
  • PCR assay development
  • Diagnostic medical devices

Where Sentinel Diagnostics is headquartered

Location

Headquarters

HQ city
Milano
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

Sentinel Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. IVD Products Manufacturing and Sales: Sentinel Diagnostics generates revenue through the research, development, and manufacturing of In Vitro Diagnostic products. Product lines include molecular diagnostics (STAT-NAT kits for COVID-19, virology, VRE, parasitology), clinical chemistry, FIT (Fecal Immunochemical Test) line, and laboratory reagents. Products are sold directly to clinical laboratories and healthcare facilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based pricing for clinical laboratories

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Sentinel Diagnostics product offering

Product offering

Core offering

Sentinel Diagnostics researches, develops, and manufactures In Vitro Diagnostic (IVD) medical devices for clinical laboratories. Its portfolio includes proprietary lyophilized real-time PCR kits (STAT-NAT®) for molecular diagnostics, fecal immunochemical tests (FIT line) for colorectal cancer screening, clinical chemistry reagents, and automated instruments (SENTiNAT®, SENTiFIT®). Products are sold directly to clinical laboratories and healthcare facilities, primarily in the EU and selected international markets.

Product overview

Sentinel Diagnostics is a leader in Research and Development and Manufacturing of IVD (In Vitro Diagnostic) products based in Milan, Italy. The company operates three main product lines: (1) STAT-NAT® line featuring proprietary lyophilized real-time PCR technology for molecular diagnostics with room-temperature stable reagents, including COVID-19 molecular and serological assays, virology panels, healthcare-associated infection tests (VRE), and parasitology kits, supported by the SENTiNAT® instrument family (200, MICRO, X48); (2) FIT line providing Fecal Immunochemical Tests (FOB Gold®, CALiaGold®, PYLiaGold) for colorectal cancer screening, run on SENTiFIT® 270 automated analyzers; and (3) Laboratory line encompassing molecular biology reagents, clinical chemistry, dedicated reagents, and chromatography products acquired through Eureka S.r.l. The company also offers lyophilization services. Sentinel Diagnostics acquired Eureka S.r.l. in February 2023 to expand its diagnostic portfolio and assay offerings for clinical laboratories.

Differentiator

Problem solved

Functional benefit

Brands

  • STAT-NAT®: Stabilized Amplification Technology - proprietary technology that stabilizes enzyme activity for long-term storage without temperature-controlled requirements
  • FOB Gold®
  • CALiaGold®
  • PYLiaGold
  • SENTiFIT®
  • SENTiFOB®
  • SENTiNAT®

Products and services

  • STAT-NAT® molecular diagnostics line Proprietary lyophilized real-time PCR technology platform with room-temperature stable reagents for molecular diagnostics. Includes kits for COVID-19, virology, healthcare-associated infections, and parasitology applications, sold to clinical laboratories.
  • FIT line (Fecal Immunochemical Test) Fecal Immunochemical Test (FIT) product line for colorectal cancer screening, including FOB Gold®, CALiaGold®, and PYLiaGold assays paired with SENTiFIT® instruments, sold to clinical laboratories and screening programs.
  • STAT-NAT® COVID-19 MULTI Lyophilized one-step multiplex Real-Time RT-PCR mix for qualitative detection of SARS-CoV-2 RNA in human respiratory tract specimens, available in all-in-one tube and high-throughput formats for clinical laboratories.
  • STAT-NAT® Pluri CoV-2-FLU-RSV Multiplex Real-Time RT-PCR for simultaneous qualitative detection of SARS-CoV-2, Influenza A&B, and RSV in human respiratory specimens in a single reaction, used by clinical laboratories for respiratory pathogen differentiation.
  • STAT-NAT® SARS-CoV-2 (3-gene) 3-gene based Real-Time RT-PCR kit for qualitative detection of SARS-CoV-2 targeting RdRp, N, and E genes, designed to be unaffected by virus mutations, for use in clinical laboratories.
  • COVID-19 Anti-S1 Total Ab Immunoturbidimetric test for quantitative and qualitative detection of total antibodies against the Spike RBD S1 protein of SARS-CoV-2 in human serum, run on SENTiFIT® analyzers in clinical laboratories.
  • COVID-19 Anti-NC Total Ab Immunoturbidimetric test for quantitative and qualitative detection of total antibodies against the Nucleocapsid protein of SARS-CoV-2 in human serum, run on SENTiFIT® analyzers.
  • STAT-NAT® VRE Lyophilized Real-Time PCR mix for rapid detection of Vancomycin-Resistant Enterococcus (VRE), identifying and differentiating vanA and vanB genes in a single tube, for use in clinical and hospital laboratories.
  • STAT-NAT® virology kits Portfolio of lyophilized Real-Time PCR kits for virology applications including detection of HAdV, CMV, BKV, VZV, Parvo B19, HSV 1&2, HHV-6, HHV-7, HHV-8, EBV, and JCV, used by clinical laboratories.
  • STAT-NAT® Leishmania spp. STAT-NAT® kit for molecular detection of Leishmania spp. parasites, used in clinical and parasitology laboratories.
  • STAT-NAT® Pathomag extraction kit Magnetic beads-based nucleic acid extraction kit optimized for respiratory samples, enabling rapid purification of viral RNA/DNA and bacterial DNA, with 120 extractions per kit and room temperature storage.
  • STAT-NAT® Total DNA/RNA extraction kit Extraction kit for isolating pathogen RNA and DNA, compatible with multiple clinical sample types and designed for high extraction efficiency at low viral titers, used by clinical laboratories.
  • SENTiNAT® 200 Sample-to-result PCR platform and walk-away system with automatic result interpretation, designed for medium to high-throughput automated molecular diagnostics workflows in clinical laboratories.
  • SENTiNAT® MICRO Compact PCR amplification instrument designed for manual molecular diagnostics workflows in clinical laboratory settings.
  • SENTiNAT® X48 Automatic nucleic acid extraction and PCR set-up instrument used by clinical laboratories to prepare molecular diagnostics assays.
  • SENTiFIT® 270 High-speed, fully automated quantitative analyzer for clinical chemistry and immunoturbidimetric assays, including FIT and serological tests, used in clinical laboratories.
  • FOB Gold® Fecal Immunochemical Test (FIT) assay for colorectal cancer screening, run on SENTiFIT® automated analyzers in clinical laboratories.
  • CALiaGold® Fecal Immunochemical Test (FIT) assay within the FIT product line, used for fecal immunochemical testing in clinical laboratories.
  • PYLiaGold Fecal Immunochemical Test assay variant within the FIT product line, used for pepsinogen testing in clinical laboratories.
  • Chromatography products (Eureka) Chromatography diagnostic kits acquired through the February 2023 acquisition of Eureka S.r.l., expanding Sentinel's diagnostic portfolio for clinical laboratories.

Companies that use Sentinel Diagnostics

Customer profile

Segments2 records

Ideal customer profiles2 records

Sentinel Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Sentinel Diagnostics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eureka S.r.l.coreStrategic or Co-development Partner · 1 February 2023In February 2023, Sentinel Diagnostics acquired Eureka S.r.l. to expand its diagnostic portfolio and assay offerings for clinical laboratories. This acquisition expanded Sentinel's product offerings in the chromatography space (referenced as www.eurekakit.com on their website).

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Sentinel Diagnostics competitors and assessment

Company assessment

Direct peers

  • ELITech Group: Mid-sized European IVD manufacturer offering molecular diagnostics (PCR) and clinical chemistry reagents to clinical laboratories — closely comparable scale and product structure to Sentinel.
  • DiaSorin: Italian-headquartered IVD company with overlapping molecular diagnostics, clinical chemistry, and immunoassay product lines sold through clinical laboratories — direct European peer with similar customer base and product mix.

Broad incumbents

  • Hologic: Diversified diagnostics player with Panther molecular diagnostic systems and assays targeting women's health, infectious disease, and HAIs — competes with Sentinel for clinical-lab molecular placements.
  • Roche Diagnostics: World's largest IVD manufacturer covering molecular diagnostics, clinical chemistry, immunoassays, and laboratory automation — broadest incumbent reference benchmark for Sentinel's full portfolio.
  • QIAGEN: Major provider of molecular diagnostics reagents, extraction kits, and PCR assays to clinical laboratories — directly competes in extraction and PCR reagent categories sold by Sentinel.
  • bioMérieux: Global IVD leader with strong molecular diagnostics and clinical microbiology portfolios serving clinical laboratories — broad incumbent competing on respiratory panels, HAIs, and reagents.
  • Cepheid (Danaher): Global leader in sample-to-result molecular diagnostics (GeneXpert) for infectious disease and healthcare-associated infections — competes head-to-head with SENTiNAT and STAT-NAT in clinical-lab molecular IVD.
  • Abbott Diagnostics: Global IVD leader with molecular (m2000, Alinity m), immunoassay, and clinical chemistry systems — competes across Sentinel's menu with clinical-laboratory customers.

Emerging players

  • Seegene: Molecular diagnostics company specializing in multiplex syndromic PCR assays (respiratory, gastrointestinal) — comparable technology overlap with Sentinel's STAT-NAT multiplex panels.

Regional players

  • Eurospital: Italian diagnostics manufacturer producing IVD reagents and clinical chemistry products for Italian and European clinical laboratories — comparable regional scale and end-market focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Sentinel Diagnostics social profiles

Digital presence

Sentinel Diagnostics compliance and trust

Trust signal

Compliance8 records

Sentinel Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sentinel Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

Sentinel Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Sentinel Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sentinel Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentinel Diagnostics

What does Sentinel Diagnostics do?

Sentinel Diagnostics researches, develops, and manufactures In Vitro Diagnostic (IVD) medical devices for clinical laboratories. Its portfolio includes proprietary lyophilized real-time PCR kits (STAT-NAT®) for molecular diagnostics, fecal immunochemical tests (FIT line) for colorectal cancer screening, clinical chemistry reagents, and automated instruments (SENTiNAT®, SENTiFIT®). Products are sold directly to clinical laboratories and healthcare facilities, primarily in the EU and selected international markets.

Is Sentinel Diagnostics a public or private company?

Sentinel Diagnostics is a private company. It is classified as unknown and is currently operating.

When was Sentinel Diagnostics founded?

Sentinel Diagnostics was founded in 2009. It employs 101 to 250 people.

Where is Sentinel Diagnostics based?

Sentinel Diagnostics is headquartered in Milano, Italy, in the Europe region.

How does Sentinel Diagnostics make money?

One revenue line is on record: IVD Products Manufacturing and Sales.

Who are Sentinel Diagnostics's main competitors?

Direct peers on record are ELITech Group and DiaSorin. Broad incumbents are Hologic, Roche Diagnostics, QIAGEN, bioMérieux, Cepheid (Danaher) and Abbott Diagnostics. Seegene is listed as an emerging player. Eurospital is listed as a regional player.

Does Sentinel Diagnostics have an API?

No public API is recorded for Sentinel Diagnostics.

What industry is Sentinel Diagnostics in?

Sentinel Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Sub-Segments Transforming the Therapeutic Drug Monitoring Market LandscapeThe therapeutic drug monitoring market is projected to grow to $4.09 billion by 2030 at a CAGR of 11.2%, driven by rising demand for precision medicine, automated diagnostics, and real-time monitoring methods. In February 2023, Sentinel Diagnostics acquired Eureka S.r.l. to expand its diagnostic portfolio and assay offerings for clinical laboratories. In June 2024, Bio-Rad Laboratories launched novel anti-idiotypic and anti-MMAE antibodies for bioanalytical assays, enhancing drug level assessments and immune response monitoring for antibody-drug conjugates.PR NewswireSENTINEL DIAGNOSTICS LANÇA SENTINAT® 200, O SISTEMA TOTALMENTE AUTOMATIZADO DA AMOSTRA AO RESULTADO PARA O DIAGNÓSTICO DE INFECÇÕES VIRAISSentinel CH. SpA announced the launch of SENTiNAT® 200, a fully automated diagnostic system for viral infections, along with STAT-NAT® SN200 PCR test kits. The platform is designed for medium-to-high throughput laboratories, capable of analyzing up to 15 viruses in four hours while reducing human error through integrated software and barcode reading. These CE-marked solutions utilize patented dry-freeze technology for reagent stability at room temperature.PR NewswireSENTINEL DIAGNOSTICS LANZA SENTINAT® 200, EL SISTEMA TOTALMENTE AUTOMATIZADO DE MUESTRA A RESULTADOS PARA EL DIAGNÓSTICO DE INFECCIONES VIRALESSentinel Diagnostics (Sentinel CH. SpA) announced the launch of SENTiNAT® 200, a fully automated sample-to-result system for viral infection diagnosis, along with STAT-NAT® SN200 real-time PCR tests for quantitative detection of 10 viruses. The platform processes 1 to 48 samples within four hours, can test up to 15 viruses simultaneously, and features cloud-based software for remote data access. The CE-IVDR and CE-IVD marked kits are designed for medium-to-high throughput laboratories and use patented lyophilization technology for long-term room temperature stability.Clinical Lab ProductsSentinel Launches Automated High Throughput Analyzer for Fecal Immunochemical TestingSentinel Diagnostics launched the SENTiFIT 800, an automated high-throughput analyzer for fecal immunochemical testing. The system processes up to 550 tests per hour and is compatible with FOB Gold and CALiaGold reagents. It aims to support colorectal cancer screening programs with full automation and traceability.BioSpaceSentinel Diagnostics Launches a Totally Automated High Throughput Analyzer for Fecal Immunochemical TestingSentinel Diagnostics launched the SENTiFIT 800, a fully automated high-throughput analyzer for fecal immunochemical testing. The system processes up to 550 tests per hour and 1 million tests annually, reducing hands-on time and manual errors. It is CE-marked and compatible with FOB Gold and CALiaGold reagents.GlobeNewswireMainz Biomed Appoints Key Clinical Trial Partners for ColoFuture StudyMainz Biomed announced partnerships with Sentinel Diagnostics and Alcedis GmbH to support its ColoFuture clinical study on colorectal cancer detection. The study will enroll over 600 patients at two centers in Norway and Germany, with enrollment expected to complete in the second half of 2022 and results reported in early 2023.YahooQIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD MarkQIAGEN received CE-IVD certification for its NeuMoDx HAdV Quant Assay for the EU, enabling non-COVID-19 testing in the US and Europe. The assay is the 15th in the NeuMoDx menu, developed with Sentinel Diagnostics, and supports random access with LDTs. QIAGEN plans FDA submissions in 2021.PR NewswireSentinel Diagnostics lanza dos nuevas pruebas serológicas para el SARS-CoV-2Sentinel Diagnostics, an Italian in vitro diagnostics company, announced on May 4, 2021 the launch of two new serological tests — COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab — for detecting total antibodies against SARS-CoV-2 in human serum. The tests, which run on automated analyzers such as the Sentinel SENTIFIT®270, can process hundreds of results per hour and distinguish between vaccinated individuals and those naturally infected by targeting different viral proteins (Spike RBD S1 and Nucleocapsid). The company developed the tests to support public health decision-making by enabling rapid assessment of community immunity status amid ongoing vaccination campaigns.PR NewswireSentinel Diagnostics Launches Two New Serological Tests To Quickly Assess The Immunoresponse To SARS-CoV-2Sentinel Diagnostics, an Italian in vitro diagnostics company, announced the launch of two new serological tests (COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab) for detecting total antibodies to SARS-CoV-2 in human serum. The tests can process hundreds of results in one hour with first results available in approximately 10 minutes, and are designed to distinguish vaccinated individuals from those who were naturally infected. The company developed these assays to support public health decisions and enable continuous monitoring of immune response following infection or vaccination.PR NewswireSentinel Diagnostics lança dois novos testes serológicos para avaliar rapidamente a resposta imune ao SARS-CoV-2Sentinel Diagnostics, an Italian in vitro diagnostics company with over 35 years of experience, announced on May 4, 2021 the launch of two new serological tests for detecting total antibodies (IgA, IgG, and IgM) against SARS-CoV-2: COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab. The tests, which process hundreds of results in one hour using immunoturbidimetric methodology, help distinguish vaccinated individuals from those naturally infected and support public health monitoring of vaccination campaign effectiveness. Both tests deliver initial results in approximately 10 minutes when run on the Sentinel SENTIFIT®270 analyzer or other automated platforms.